An Open-Label Study of Tolododekin Alfa (ANK-101) in Renal Allograft Recipients With Resectable, High-Risk Cutaneous Squamous Cell Carcinoma

NCT07100925 Phase 1 NOT_YET_RECRUITING

A study of tolododekin alfa (also known as ANK-101) administered prior to surgery in kidney transplant participants that also have high-risk cutaneous squamous cell carcinoma (CSCC).

Details

Lead sponsor	Ankyra Therapeutics, Inc
Phase	Phase 1
Status	NOT_YET_RECRUITING
Enrolment	20
Start date	2025-12-15
Completion	2030-12

Conditions

• Cutaneous Squamous Cell Carcinoma (CSCC)
• Renal Transplant
• Solid Tumor
• Solid Tumor Cancer

Interventions

• tolododekin alfa

Primary outcomes

• Major Pathological Response (MPR) rate — 3 months
  The percentage of participants who have ≤ 10% viable cancer cells in the surgical pathology sample among all response evaluable participants.